Recent advances in delivery systems for anti-HIV1 therapy.
In the last years, different non-biological and biological carrier systems have been developed for anti-HIV1 therapy. Liposomes are excellent potential anti-HIV1 carriers that have been tested with drugs, antisense oligonucleotides, ribozymes and therapeutic genes. Nanoparticles and low-density lipoproteins (LDLs) are cell-specific transporters of drugs against macrophage-specific infections such as HIV1. Through a process of protein transduction, cell-permeable peptides of natural origin or designed artificially allow the delivery of drugs and genetic material inside the cell. Erythrocyte ghosts and bacterial ghosts are a promising delivery system for therapeutic peptides and HIV vaccines. Of interest are the advances made in the field of HIV gene therapy by the use of autologous haematopoietic stem cells and viral vectors for HIV vaccines. Although important milestones have been reached in the development of carrier systems for the treatment of HIV, especially in the field of gene therapy, further clinical trials are required so that the efficiency and safety of these new systems can be guaranteed in HIV patients.
Lanao
José M
JM
Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Salamanca, Salamanca, Spain. jmlanao@usal.es
Briones
Elsa
E
Colino
Clara I
CI
D000818:Animals; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000494:pharmacology*; D004337:Drug Carriers; D016503:Drug Delivery Systems; D015316:Genetic Therapy; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D033581:Stem Cell Transplantation
D019380:Anti-HIV Agents; D004337:Drug Carriers